OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
January 13, 2022
The collaboration between Bristol Myers Squibb and Century Therapeutics will combine Century’s iPSC-derived allogeneic cell therapy platform with Bristol Myers Squibb’s expertise in cell therapy and oncology drug development.
January 11, 2022
The agreement expands Pfizer’s access to LNP formulation technology for mRNA vaccines and therapeutics.
January 07, 2022
FDA has cleared an IND from Poseida Therapeutics, allowing continued development of the company’s allogeneic CAR-T cell therapy candidate for treating multiple solid tumors.
January 05, 2022
Particle analysis provides assurances of the quality and performance of the final dosage form in pharmaceutical development.
Sample preparation tends to be manually labor intensive, but automating this step helps streamline the glycosylation monitoring workflow.
January 03, 2022
Warp speed is amazoning pharma practices and protocols.
A new focus on speed to market creates challenges for facility design and construction.
Dosage form and patient needs drive excipient choice.
Poor solubility remains a big issue for drug development and, as such, is driving innovation in approaches and use of novel technologies to help overcome the associated challenges.
January 02, 2022
There is need for training personnel in various analytical skill sets for biologic drug substance testing.